Access Pharmaceuticals Signs Agreement With Leading Biopharmaceutical Company to Develop CobOral Formulation of Widely-Marketed Injectable

Access Pharmaceuticals, Inc., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has entered into a pre-licensing feasibility agreement with a leading biopharmaceutical company to develop an oral formulation of an undisclosed prostate cancer compound utilizing its proprietary vitamin B-12-based CobOral Drug Delivery Technology.

Related Posts

Comments are closed.